Valneva have released results from their phase 3 vaccine study (VLA2001). Stating that the trial has successfully met both co-primary end points. This trial compared the efficacy and effectiveness of the Valneva Covid-19 vaccine against the AstraZeneca vaccine. A total of 4012 people, aged 18 years and above were recruited to this clinical trial, across 26 trial sites in the UK.
